No Data
Acumen Pharmaceuticals Exercises Option For Development, Production, Commercialization Of Two Candidates To Treat Alzheimer's Disease Through JCR Pharmaceuticals' Blood-Brain Barrier -Penetrating Technology Platform J-Brain Cargo
Express News | Jcr Pharmaceuticals Co - to Receive Tiered Royalties on Net Sales From Collaboration Products
Express News | Jcr Pharmaceuticals Co - Eligible for up to $555 Mln in Milestone Payments From Acumen Deal
Bank of America Securities Keeps Their Buy Rating on Acumen Pharmaceuticals (ABOS)
Acumen Stockholders Approve Directors and Equity Incentive Plan
Acumen Pharmaceuticals (ABOS) Gets a Buy From Bank of America Securities